In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Intrathecal Baclofen for spasticity; A compliance based Study to indicate effectiveness.

    Final Number:
    263

    Authors:
    Ahmed Alkhani; Hussam Abo Shaer

    Study Design:
    Clinical Trial

    Subject Category:
    Movement Disorders

    Meeting: 2014 ASSFN Biennial Meeting

    Introduction: Intrathecal administration of baclofen via a continuous programmable buttery based pump is a recognized option in the treatment of medically refractory spasticity. Objective outcome evaluation is usually based on clinical evaluation of the spastic muscles groups. Such evaluations my not indicate functional improvement in this heterogeneous group of patients. In this study, patient's compliance after two years of implanting the pump device was set as an indication of effectiveness of the treatment as appreciated by the patients themselves or their caregivers.

    Methods: A cohort group of 35 patients were admitted to the hospital for an intrathecal baclofen trial. A total of 27 patients were implanted with battery based programmable baclofen pump. All patients were referred to a specialized outpatient clinic for medication refilling and adjustment of rate of infusion. All follow-up visits were supported by national health services and free of any charges including transportation. All patients had either minimum of two years follow-up or discontinuation of therapy for different reasons. All patients' medical data were collected prospectively and reviewed at the time of the study.

    Results: Twenty seven patients (15 males and 12 females) were included in the study. Patient`s age ranged from 7 to 69 years (mean of 29 year). Documented etiologies of spasticity included trauma, cerebral palsy, familial spasticity, multiple sclerosis, tumors and others. All patients were operated by the same surgeon (senior author) following the same operative and post operative protocol. At the 2 years post implantation set point, 20 patients continue to comply with the treatment. All of them reported at least moderate improvement in the symptoms that deserve compliance with the therapy. The other 7 patients had the pump removed as decided by the patients themselves or the caregivers (5 patients), recurrent infection(1patient) and death secondary to the primary disease (1 patient).

    Conclusions: At 2 years follow-up after implantation of programmable intrathecal baclofen pump therapy for intractable spasticity, 74% of patients continue to comply with the treatment.

    Patient Care: A new approach to evaluate the effectiveness of this treatment modality.

    Learning Objectives: effectiveness of intrathecal Baclofen therapy for spasticity

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy